RecruitingSubdural Hematoma
MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma
Eligible age
18–90 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.
Sponsor: Arsenal Medical, Inc.
You may qualify if…
- ✓ Participant whose age is ≥ 18 and ≤ 90 years;
- ✓ Pre-morbid mRS ≤ 2;
- ✓ Confirmed diagnosis of subacute or chronic subdural hematoma that measures ≥10 mm in greatest thickness;
- ✓ Participant presents with one or more of the following corroborating neurological symptoms: headache; cognitive decline; speech difficulty; gait impairment or imbalance; focal neurological deficit; and/or seizure, within the last 30 days;
- ✓ Participant is planned for middle meningeal artery embolization within ±7 days of surgical evacuation of hematoma via burr hole or craniotomy;
- ✓ Participant or Legally Authorized Representative/Person Responsible for consenting on their behalf understands the nature of the procedure, consents to participation in the study and provides a signed informed consent form;
- ✓ Participant (woman of child-bearing potential) with a current negative pregnancy test who has agreed to an appropriate method of contraception throughout the trial;
- ✓ Participant is willing to return to the investigational site for follow-up visits.
You may not qualify if…
- ✕ Diagnosed with acute SDH
- ✕ Participant with prior embolization of either MMA
- ✕ Participant with urgent or emergent (within 1 hour of assessment) subdural hematoma evacuation needed
- ✕ Participant with bilateral SDH where both sides require surgery or contralateral SDH \>5mm in greatest thickness
- ✕ Participant identified with potentially dangerous anatomic variations leading to increased procedural risk, risk of incomplete embolization, or unsafe access for MMA embolization (i.e., MMA originating from ophthalmic artery)
- ✕ Participant who presents with a meningioma ≥1 cm or \< 1 cm with mass effect
- ✕ Subjects with conditions placing them at high-risk for ischemic stroke who cannot be taken off anticoagulants for at least 7 days post-surgery
- ✕ Participant currently undergoing radiation therapy for carcinoma or sarcomas of the head or neck region
Where it's recruiting
Connecticut
New Haven
Washington
Seattle
Source: ClinicalTrials.gov · NCT07541404 · last updated 2026-09-30